Cubist Systematic Strategies LLC Purchases 53,216 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Cubist Systematic Strategies LLC significantly increased its holdings in Structure Therapeutics Inc., boosting its stake by 3,326.0% to a total of 54,816 shares, valued at approximately $949,000.
• Structure Therapeutics recently reported an EPS of ($0.36), missing analysts' expectations while analysts project a -0.82 EPS for the current year.
• Research firms have mixed opinions on Structure Therapeutics, with eight analysts rating it as a Buy and a consensus price target of $75.71, despite recent price target reductions from firms like HC Wainwright and JMP Securities.

Cubist Systematic Strategies LLC increased its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 3,326.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 54,816 shares of the company's stock after purchasing an additional 53,216 shares during the quarter. Cubist Systematic Strategies LLC owned 0.10% of Structure Therapeutics worth $949,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics during the fourth quarter worth $34,000. National Bank of Canada FI increased its position in shares of Structure Therapeutics by 1,448.2% during the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after acquiring an additional 2,766 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 310.7% during the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after acquiring an additional 3,213 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Structure Therapeutics by 663.8% during the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock worth $152,000 after acquiring an additional 7,627 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Structure Therapeutics during the first quarter worth $249,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Price Performance

GPCR stock traded up $0.03 during trading hours on Friday, reaching $20.91. The stock had a trading volume of 1,466,150 shares, compared to its average volume of 1,033,666. The stock has a market capitalization of $1.20 billion, a PE ratio of -19.91 and a beta of -1.88. The stock has a 50-day simple moving average of $18.90 and a 200 day simple moving average of $20.68. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $45.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. JMP Securities decreased their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Lifesci Capital raised shares of Structure Therapeutics to a "strong-buy" rating in a research report on Monday, September 8th. Guggenheim decreased their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Finally, HC Wainwright decreased their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, Structure Therapeutics presently has an average rating of "Buy" and an average price target of $75.71.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.